(Q37298600)

19 August 2017

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis (English)

1 reference

19 August 2017

1 reference

1 reference

Richa Mishra

1

1 reference

PMCID

3824288

19 August 2017

Vijay Singh

series ordinal

2

1 reference

PMCID

3824288

19 August 2017

Charles H Pritchard

series ordinal

3

1 reference

19 August 2017

20 December 2009

1 reference

Rheumatology International

19 August 2017

1 reference

19 August 2017

31

1 reference

19 August 2017

4

1 reference

19 August 2017

481-484

1 reference

https://scigraph.springernature.com/pub.10.1007/s00296-009-1307-7

19 August 2017

0 references

cites work

Tumor necrosis factor inhibitors and infection complications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

The effects of rituximab on immunocompetency in patients with autoimmune disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

The potential utility of B cell-directed biologic therapy in autoimmune diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Problems encountered during anti-tumour necrosis factor therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

B cell-targeted therapy for rheumatoid arthritis: an update on the evidence

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Epidemiology and burden of illness of rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

6 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00296-009-1307-7

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3824288

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20091035

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00296-009-1307-7

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

PMCID

3824288